<DOC>
	<DOCNO>NCT00073372</DOCNO>
	<brief_summary>The purpose study determine effectiveness abciximab treatment acute ischemic stroke .</brief_summary>
	<brief_title>A Study Effectiveness Safety Abciximab Patients With Acute Ischemic Stroke ( AbESTT-II )</brief_title>
	<detailed_description>Abciximab drug prevents platelet stick together form clot . There limited study use abciximab treatment stroke . This phase III , multicenter , randomize , double-blind , placebo-controlled , parallel group study design assess effectiveness safety abciximab treatment acute ischemic stroke , help dissolve clot brain artery blood oxygen flow well may less brain damage . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive either Abciximab : 0.25 mg/kg bolus ( maximum 30 mg ) follow 0.125 µg/kg/min infusion ( maximum 10 µg/min ) 12 hour bolus placebo follow infusion 12 hour</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Patients diagnosis acute ischemic stroke onset within 5 hour 30 minute randomization plan treatment initiation within 6 hour onset After 600 patient enrol previous criterion , new criterion enrollment , patient diagnosis acute ischemic stroke onset within 4 hour 30 minute randomization plan treatment initiation within 5 hour onset Patients participation another study investigational drug device within last 30 day , prior participation present study , plan participation another trial Patients symptom suggestive subarachnoid hemorrhage Female patient know pregnant , lactating , positive indeterminate pregnancy test Patients neurological deficit lead stupor coma Patients minor stroke</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>abciximab</keyword>
	<keyword>ReoPro</keyword>
	<keyword>drug safety</keyword>
	<keyword>drug efficacy</keyword>
	<keyword>intracranial hemorrhage</keyword>
	<keyword>stroke</keyword>
</DOC>